
HCA Healthcare (HCA) Stock Forecast & Price Target
HCA Healthcare (HCA) Analyst Ratings
Bulls say
HCA Healthcare's financial position remains robust, ending the year with $1.04 billion in cash and $5.78 billion in available credit, coupled with an 8.3% increase in dividends to $0.78 per share. The company's projected EBITDA growth of 7.6% and improved EBITDA margins of 21.1% highlight effective management strategies, particularly in operational efficiencies. Furthermore, HCA's strategic capital expenditure increase to $5.0-$5.5 billion for 2026, aimed at expanding high acuity programs and inpatient capacity, underscores a commitment to enhancing service offerings and driving future growth.
Bears say
HCA Healthcare is anticipating a significant decline in utilization of care, projecting a 30% reduction for the approximately 80%-85% of patients expected to be uninsured, which could negatively impact overall revenue. Additionally, the company forecasts a substantial decrease of $250-$450 million in DPP net benefits for 2026, largely due to the cessation of certain Medicaid programs and a reduction in historical contributions from specific states. Furthermore, the adjusted EBITDA outlook for 2026, estimated at $15.55-$16.45 billion, reflects the presence of headwinds associated with these challenges, indicating potential pressure on profitability.
This aggregate rating is based on analysts' research of HCA Healthcare and is not a guaranteed prediction by Public.com or investment advice.
HCA Healthcare (HCA) Analyst Forecast & Price Prediction
Start investing in HCA Healthcare (HCA)
Order type
Buy in
Order amount
Est. shares
0 shares